BRCA1/2基因检测与预防策略成本效益数据集

数据集获取（Figshare）

• 源站标题：DataSheet_1_Cost-Effectiveness of BRCA 1/2 Genetic Test and Preventive Strategies: Using Real-World Data From an Upper-Middle Income Country.docx
• DOI：10.3389/fonc.2022.951310.s001
• 发布日期：2022-07-11
• 文件数：1 个
• 文件总体积：909.32 KB
• 源站页面：https://frontiersin.figshare.com/articles/dataset/DataSheet_1_Cost-Effectiveness_of_BRCA_1_2_Genetic_Test_and_Preventive_Strategies_Using_Real-World_Data_From_an_Upper-Middle_Income_Country_docx/20281152

命令行下载

curl -L -o "DataSheet_1_Cost-Effectiveness of BRCA 1/2 Genetic Test and Preventive Strategies: Using Real-World Data From an Upper-Middle Income Country.docx" "https://ndownloader.figshare.com/files/36223782"

文件清单

• DataSheet_1_Cost-Effectiveness of BRCA 1/2 Genetic Test and Preventive Strategies: Using Real-World Data From an Upper-Middle Income Country.docx（909.32 KB）

文件总体积 909.32 KB（源站 API 实测）。

数据加载示例（图像类）

from PIL import Image
import glob, os

files = (glob.glob(os.path.join(path, "**", "*.png"), recursive=True)
       + glob.glob(os.path.join(path, "**", "*.jpg"), recursive=True)
       + glob.glob(os.path.join(path, "**", "*.tif"), recursive=True))
print("图像文件数:", len(files))
img = Image.open(files[0]); print("尺寸/模式:", img.size, img.mode)

# torchvision Dataset 方式:
# from torchvision import datasets
# ds = datasets.ImageFolder(path)  # 要求 子目录=类别

目录组织与标注格式以源站说明和下载后实际文件为准。

数据说明

Although BRCA1/2 genetic testing in developed countries is part of the reality for high-risk patients for hereditary breast and ovarian cancer (HBOC), the same is not true for upper-middle-income countries. For that reason, this study aimed to evaluate whether the BRCA1/2 genetic test and preventive strategies for women at high risk for HBOC are cost-effective compared to not performing these strategies in an upper-middle-income country. Adopting a payer perspective, a Markov model with a time horizon of 70 years was built to delineate the health states for a cohort of healthy women aged 30 years that fulfilled the BRCA1/2 testing criteria according to the guidelines. Transition probabilities were calculated based on real-world data of women tested for BRCA1/2 germline mutations in a cancer reference hospital from 2011 to 2020. We analyzed 275 BRCA mutated index cases and 356 BRCA mutation carriers that were first- or second-degree relatives of the patients. Costs were based on the Brazilian public health system reimbursement values. Health state utilities were retrieved from literature. The BRCA1/2 genetic test and preventive strategies result in more quality-adjusted life years (QALYs) and costs with an incremental cost-effectiveness ratio of R$ 11,900.31 (U$ 5,504.31)/QALY. This result can represent a strong argument in favor of implementing genetic testing strategies for high-risk women even in countries with upper-middle income, considering not only the cancer prevention possibilities associated with the genetic testing but also its cost-effectiveness to the health system. These strategies are cost-effective, considering a willingness-to-pay threshold of R$ 25,000 (U$ 11,563.37)/QALY, indicating that the government should consider offering them for women at high risk for HBOC. The results were robust in deterministic and probabilistic sensitivity analyses.

许可

CC BY 4.0

引用

学术使用请引用 DOI 10.3389/fonc.2022.951310.s001（source: https://frontiersin.figshare.com/articles/dataset/DataSheet_1_Cost-Effectiveness_of_BRCA_1_2_Genetic_Test_and_Preventive_Strategies_Using_Real-World_Data_From_an_Upper-Middle_Income_Country_docx/20281152）。